Sentences with phrase «on preclinical development»
Frost and Sullivan's survey showed that in 2002, the top 20 pharmaceutical companies spent about a third of their R&D budgets on preclinical development.
http://www.sciencemag.org/ Not exact matches
The first move sets Takeda up to work on development of FIN - 524, a preclinical therapy that contains cultured bacteria strains and which could theoretically be used to treat gut diseases.
Many of his former students that entered the business as researchers have since moved on to managerial or peripheral roles, such as technology transfer, venture capital, regulatory affairs, and preclinical and clinical development.
Platform technologies enable scientists to apply a standardized manufacturing process to multiple vaccines and create a collective database on their safety as well, which can shorten the preclinical development period to as little as several months, according to the authors.
In addition, EATRIS will seek to identify inconsistencies in the national regulatory frameworks while offering consultation on preclinical vaccine development (WP16).
These forward - looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical development of its drug candidates and advance such candidates into clinical development, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as those relating to manufacturing, the regulatory process, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward - looking statements.
These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, uncertainty regarding potential future deterioration in the market for auction rate securities which could result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.
Proclara Biosciences Presents Preclinical Data Supporting the Development of GAIM - Based Therapies for Peripheral Amyloidoses at the 16th International Symposium on Amyloidosis March 28, 2018
Our group is specifically working on improvement of islet isolation and transplantation protocols in clinical practice and the development of novel therapeutic options in the field of beta cell replacement with a clear translational «bench to bedside» approach by linking experimental research with preclinical and clinical work:
Proclara Biosciences Presents Preclinical Data Supporting the Development of GAIM - Based Therapies for Peripheral Amyloidoses at the 16th International Symposium on Amyloidosis
S.R.P. is a consultant for Pfizer vaccines and has a sponsored program on preclinical vaccine development with Merck.
Scientists and vaccine developers involved in EVI projects presented project progress and research findings, highlighting one of the most important areas of EVI's activities; translation of research on diseases of poverty vaccines, focusing on early stages from preclinical to clinical development through harmonisation.
For the main conference on September 25 and 26, the event will be structured around 3 plenary sessions, introduced by keynote speakers: Session 1: The Funder, Developer and Regulator as Partners in Innovation Session 2: Novel approaches in clinical development Session 3: Developing more predictive preclinical tools to better reach proof of concept
These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.
Building on his Ph.D. research developing magnetic nanoparticle tracers for Magnetic Particle Imaging (MPI), he co-founded LodeSpin Labs LLC where he led the preclinical development of the first long - circulating blood pool MPI tracer.
The operationalization of mild cognitive impairment (MCI) led to targeting earlier symptomatic cases of the illness and treatment strategies based less on pathology and more on a chance to halt or slow decline than there would be earlier in the disease.1 With the development of amyloid imaging, MCI due to AD diagnosis was refined, 2 and early - stage AD was extended further to include preclinical AD, 3 wherein a positive amyloid positron emission tomography (PET) scan or diagnostic low levels of cerebrospinal fluid β - amyloid (Aβ) indicated the presence of pathology in people who were cognitively normal.
These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, the outcome of the review of the continued listing of our common stock on The Nasdaq Stock Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.
The lab is currently a part of a multi-institutional group working on developing a prophylactic HIV vaccine under a five year Integrated Preclinical / Clinical AIDS Vaccine Development Program grant from the National Institutes of Allergy and Infectious Disease (NIAID).
The company's preclinical and discovery programs are focused on the development of new treatments for multiple therapeutic areas, including neuromuscular disease, oncology and infectious disease.
Given emerging preclinical and clinical findings demonstrating the importance of both genetic and environmental (e.g., care giving and social supports) factors in determining the consequences of early stress, we examined the moderating role of the 5 - HTTLPR and social supports on the development of depression in maltreated children.